TransCode Therapeutics, Inc.
RNAZ · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $535 | $517 | $99 | $42 |
| Gross Profit | -$535 | -$517 | -$99 | -$42 |
| % Margin | – | – | – | – |
| R&D Expenses | $9,615 | $12,264 | $10,232 | $2,754 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $5,510 | $6,638 | $8,335 | $3,355 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $15,126 | $18,902 | $18,567 | $6,109 |
| Operating Income | -$15,661 | -$19,419 | -$18,666 | -$6,151 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$1,094 | $872 | $1,101 | -$692 |
| Pre-Tax Income | -$16,755 | -$18,546 | -$17,565 | -$6,843 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$16,755 | -$18,546 | -$17,565 | -$6,843 |
| % Margin | – | – | – | – |
| EPS | -47.14 | -3,453.65 | -73,187.37 | -648 |
| % Growth | 98.6% | 95.3% | -11,194.3% | – |
| EPS Diluted | -47.14 | -3,453.53 | -1,080 | -648 |
| Weighted Avg Shares Out | 356 | 5 | 16 | 11 |
| Weighted Avg Shares Out Dil | 356 | 5 | 16 | 11 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $5 | $20 | $1 |
| Interest Expense | $27 | $56 | $17,565 | $95 |
| Depreciation & Amortization | $535 | $517 | $99 | $42 |
| EBITDA | -$16,193 | -$17,973 | -$17,466 | -$6,706 |
| % Margin | – | – | – | – |